MedDataX Logo

Estimation of Dynamics of Humoral and Cellular Immunity in COVID-19 Patients

NCT ID: NCT04649840

Last Updated: 2021-12-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

274 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-01

Study Completion Date

2021-12-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of the project: to study the dynamics of the humoral and cellular immunity in patients after pneumonia caused by the SARS-CoV-2 virus at different time intervals, in order to predict the duration of immune protection

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* to form study groups of patients (at least 60 patients in total) who have recovered from pneumonia of varying severity caused by the SARS-CoV-2 virus (at least 30 patients in each of the groups of patients who have had pneumonia in moderate and severe forms);
* to investigate the parameters of cellular immunity (the content of antigen-specific T-cells to the main viral antigens - proteins S, N, M) in patients of different groups included in the trials, in dynamics 3, 6, 9 and 12 months after the COVID-19-associated pneumonia;
* to investigate the indicators of humoral immunity (the content of IgG to the main viral antigens - proteins S, N, M) in patients of different groups included in the trials, in dynamics 3, 6, 9 and 12 months after the COVID-19-associated pneumonia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COVID-19 moderate

moderate COVID-19 associated pneumonia

Humoral and cellular immunity

Intervention Type DIAGNOSTIC_TEST

Humoral (IgG) and cellular (antigen-specific cells) immunity

COVID-19 severe

severe COVID-19 associated pneumonia

Humoral and cellular immunity

Intervention Type DIAGNOSTIC_TEST

Humoral (IgG) and cellular (antigen-specific cells) immunity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Humoral and cellular immunity

Humoral (IgG) and cellular (antigen-specific cells) immunity

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients recovered from the COVID-19 associated pneumonia (moderate and severe) in 1-3 month interval before inclusion into the trial;

Exclusion Criteria

* cancer;
* drug and alcohol addiction;
* autoimmune diseases.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Belarusian State Medical University

OTHER

Sponsor Role collaborator

The Republican Research and Practical Center for Epidemiology and Microbiology

OTHER

Sponsor Role collaborator

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andrei Hancharou, MD, PHD

Role: STUDY_DIRECTOR

Director

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

Minsk, , Belarus

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belarus

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IBCE_COVID19_Immunity

Identifier Type: -

Identifier Source: org_study_id